1 – 10 of 66
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor : The AGITG ALT-GIST intergroup randomized phase II trial: Clinical Studies
- Contribution to journal › Article
-
Mark
Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma
- Contribution to journal › Article
-
Mark
Capturing breast cancers’ copy-number landscape in routine pathology : Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond
- Contribution to journal › Article
- 2024
-
Mark
Quality of life for patients with advanced gastrointestinal cancer randomised to early specialised home-based palliative care: the ALLAN trial
- Contribution to journal › Article
-
Mark
Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe : the PanCareSurFup study
- Contribution to journal › Article
-
Mark
Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer : a multicentre external validation in patients who underwent surgery
- Contribution to journal › Article
-
Mark
Body mass index, triglyceride-glucose index, and prostate cancer death : a mediation analysis in eight European cohorts
- Contribution to journal › Article
-
Mark
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
- Contribution to journal › Article
-
Mark
Educational attainment in survivors of childhood cancer in Denmark, Finland, and Sweden
- Contribution to journal › Article
- 2023
-
Mark
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
- Contribution to journal › Article
